Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
|Articles|November 29, 2013
Supplements and Featured Publications
- A Data-Driven Approach to Improving Clinical and Economic Outcomes in Multiple Sclerosis [CME/CNE/CP
- Volume 19
- Issue 16 Suppl
Post Test: A Data-Driven Approach to Improving Clinical and Economic Outcomes in Multiple Sclerosis
Advertisement
Instructions
After reading “A Data-Driven Approach to Improving Clinical and Economic Outcomes in Multiple Sclerosis,” complete the program evaluation and select the single best answer to each of the posttest questions.
Participants must read each article in this supplement, complete the online posttest achieving a passing score of 70% or higher, and complete an online evaluation and request for credit. Detailed instructions on obtaining CE credit are included following the sample online posttest.
Articles in this issue
almost 13 years ago
Managed Care Aspects of Managing Multiple Sclerosisalmost 13 years ago
Management of Multiple Sclerosisalmost 13 years ago
Multiple Sclerosis UpdateAdvertisement
Related to this article
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
The Omaha-based practice will hand its inbound faxes and document management to artificial intelligence (AI) agents, with outside records retrieval to follow.
Advertisement
Advertisement
Trending on AJMC
1
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
4
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
5